Glasgow-Blatchford bleeding score is an objective, validated pre-endoscopic risk stratification tool designed to evaluate patients presenting with acute upper gastrointestinal bleeding (UGIB)1,2. Developed to determine which patients require hospital admission, blood transfusion, or urgent endoscopic intervention versus those who can be safely discharged for outpatient management, the score integrates readily available clinical and laboratory parameters without requiring prior endoscopic evaluation1. By incorporating hemoglobin, blood urea nitrogen (or urea), systolic blood pressure, heart rate, clinical presentation features (melena and syncope), and underlying comorbidities (hepatic disease and cardiac failure), the Glasgow-Blatchford Score (GBS) provides exceptional sensitivity in identifying low-risk individuals with acute upper gastrointestinal hemorrhage1,2.

1. Etiology & Risk Factors

  • Peptic Ulcer Disease (PUD): Accounting for approximately 50% of all upper gastrointestinal bleeding cases, gastric and duodenal ulcers expose submucosal arteries (such as the gastroduodenal artery), precipitating severe arterial hemorrhage.
  • Esophageal and Gastric Varices: Secondary to portal hypertension in advanced cirrhosis, variceal rupture produces massive, high-pressure venous bleeding associated with substantial morbidity and mortality.
  • Mallory-Weiss Tears: Longitudinal mucosal lacerations at the gastroesophageal junction caused by severe retching, vomiting, or coughing, typically presenting with self-limiting bleeding.
  • Erosive Gastroduodenitis & Esophagitis: Mucosal inflammation induced by nonsteroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids, heavy alcohol consumption, or severe physiological stress (critically ill patients developing stress-related mucosal disease).
  • Upper Gastrointestinal Malignancies: Gastric adenocarcinomas, esophageal squamous cell carcinomas, and stromal tumors that undergo central necrosis and ulceration, resulting in chronic or acute occult/manifest bleeding.
  • Vascular Malformations & Dieulafoy Lesions: Abnormally large submucosal tortuous arterioles that erode the overlying epithelium without preceding ulceration, causing recurrent, high-flow arterial hemorrhage.
  • Systemic Risk Factors: Advanced age, chronic kidney disease, coagulopathies, antiplatelet and anticoagulant therapy (e.g., aspirin, clopidogrel, warfarin, direct oral anticoagulants), and chronic liver or cardiac disease.

2. Pathophysiology

Acute upper gastrointestinal bleeding originates proximal to the ligament of Treitz, encompassing pathology within the esophagus, stomach, and duodenum. When mucosal integrity is compromised by acid-pepsin aggression, portal hypertension, mechanical shearing, or neoplastic invasion, underlying blood vessels are exposed to luminal contents. In arterial bleeds (such as peptic ulcers involving the gastroduodenal artery), high-pressure jets cause rapid intravascular volume depletion. In venous bleeds (such as esophageal varices), portal venous hypertension generates sustained, high-volume flow that overwhelms homeostatic mechanisms. The acute loss of circulating red blood cells and plasma volume triggers compensatory baroreceptor reflex activation, resulting in sympathetic outflow surge, peripheral vasoconstriction, and tachycardia to maintain cerebral and coronary perfusion. Simultaneously, blood proteins from the extravasated blood entering the upper gastrointestinal lumen are digested and absorbed into the portal circulation, where hepatic conversion of amino acids into urea leads to a disproportionate elevation of blood urea nitrogen relative to serum creatinine—a hallmark biochemical feature captured within the Glasgow-Blatchford scoring algorithm1,2.

Glasgow-Blatchford bleeding score — Pathophysiological Cascade & Clinical Flowchart 1 Gastrointestinal Mucosal Injury Peptic ulceration, variceal rupture, or Mallory-Weiss tear exposes submucosal vasculature. 2 Acute Luminal Hemorrhage Arterial or venous bleeding into the upper gastrointestinal tract causes acute blood loss and hypovolemia. 3 Systemic Hemodynamic Response Compensatory tachycardia and vasoconstriction occur, accompanied by urea elevation from digested blood proteins. 4 Clinical Presentation Manifests with hematemesis, melena, anemia, and elevated risk scores on the Glasgow-Blatchford scale. 5 Endoscopic Intervention Urgent hemostasis via clips, electrocoagulation, or band ligation prevents recurrent hemorrhage and mortality.

3. Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients classically present with hematemesis (bright red emesis or "coffee-ground" emesis representing oxidized gastric blood), melena (dark, tarry, foul-smelling stools resulting from bacterial degradation of hemoglobin iron as it transits the bowel), or hematochezia (bright red blood per rectum when massive upper gastrointestinal hemorrhage causes rapid intestinal transit). Non-specific symptoms include dizziness, lightheadedness, fatigue, exertional dyspnea, and syncope resulting from acute orthostatic hypotension.
  • Physical Examination & Named Clinical Signs: Assessment focuses on hemodynamic stability and signs of chronic liver disease or hypovolemia. Orthostatic vital sign changes (a drop in systolic blood pressure of greater than 20 mmHg or an increase in heart rate of greater than 20 beats per minute upon standing) indicate significant volume depletion. Abdominal examination may reveal epigastric tenderness in peptic ulcer disease, or hepatosplenomegaly, ascites, spider angiomata, palmar erythema, and caput medusae in patients with underlying cirrhosis and variceal bleeding. Digital rectal examination is mandatory to confirm the presence of melena or blood.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationUrgent upper endoscopy (esophagogastroduodenoscopy, EGD) performed within 24 hours of presentation (or within 12 hours for high-risk or hemodynamically unstable patients) to visualize bleeding sources, classify lesions using Forrest criteria, and deliver therapeutic hemostasis.
Laboratory PanelComplete blood count demonstrating normocytic or microcytic anemia with reduced hemoglobin; elevated blood urea nitrogen (BUN) out of proportion to serum creatinine due to upper gastrointestinal blood protein digestion; elevated international normalized ratio (INR) and prolonged activated partial thromboplastin time (aPTT) in coagulopathy or liver failure.
Imaging / Radiology (X-ray, US, CT, MRI)Contrast-enhanced computed tomography (CT) angiography reserved for refractory cases with ongoing massive hemorrhage where endoscopy is non-diagnostic or unfeasible, or abdominal ultrasound and Doppler studies to evaluate portal hypertension and hepatic architecture.
ECG / Histopathology / Procedural12-lead electrocardiogram to evaluate for myocardial ischemia or acute coronary syndrome secondary to demand ischemia induced by acute severe anemia and tachycardia; mucosal biopsies obtained during EGD to rule out malignancy and test for Helicobacter pylori.

5. Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Hemoglobin (g/dL or g/L)Male: 12.0–12.9 (1 pt), 10.0–11.9 (3 pts), <10.0 (6 pts). Female: 10.0–11.9 (1 pt), <10.0 (6 pts). Higher point allocation reflects profound anemia and transfusion requirements.
Blood Urea Nitrogen / UreaUrea 6.5–7.9 mmol/L (2 pts), 8.0–9.9 mmol/L (3 pts), 10.0–24.9 mmol/L (4 pts), >25.0 mmol/L (6 pts). Reflects enteral digestion and absorption of red cell protein load.
Systolic Blood Pressure (mmHg)100–109 (1 pt), 90–99 (2 pts), <90 (3 pts). Captures acute hypovolemic compromise and compensatory vasomotor failure.
Heart Rate (beats/min) & Clinical SignsHeart rate $\ge$100 bpm (1 pt); presentation with melena (1 pt); presentation with syncope (2 pts). Reflects autonomic sympathetic surge and significant hemodynamic instability.
ComorbiditiesKnown or suspected hepatic disease (2 pts); known or suspected cardiac failure (2 pts). Identifies vulnerable populations at high risk for decompensation.
Clinical Interpretation (GBS 0)A total score of 0 defines very low risk (intervention rate <1%), allowing safe outpatient management and discharge with elective outpatient workup. Scores $\ge$1 warrant hospital admission and early endoscopic evaluation.

6. Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Lower Gastrointestinal BleedingPresents predominantly with hematochezia or maroon stools rather than melena or hematemesis; normal blood urea nitrogen-to-creatinine ratio; upper endoscopy is normal, requiring colonoscopy or CT angiography.
HemoptysisExpectoration of bright red, frothy blood mixed with sputum originating from the respiratory tract; typically preceded by coughing and pulmonary symptoms rather than nausea, vomiting, or epigastric discomfort; confirmed via chest radiography and bronchoscopy.
Pseudo-Melena / Diet-Induced Stool DarkeningBlack stools caused by oral iron supplementation, bismuth subsalicylate (Pepto-Bismol), or foods such as blueberries and activated charcoal; absence of hemodynamic instability, normal hemoglobin, normal BUN, and negative fecal occult blood testing.
Aortoenteric FistulaRare, catastrophic communication between the aorta (typically near a prior aortic graft) and the duodenal lumen; classically presents as "sentinel bleeding" followed by massive, fatal hemorrhage; diagnosed via contrast-enhanced CT angiography.

7. Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Establish two large-bore peripheral intravenous lines (16-gauge or 18-gauge) or central venous access. Administer IV crystalloid fluids (normal saline or lactated Ringer's) for acute hypotension. Transfuse packed red blood cells (PRBCs) selectively, maintaining a restrictive hemoglobin threshold of 7.0 g/dL (or 8.0 g/dL in patients with preexisting cardiovascular disease). Correct severe coagulopathies with fresh frozen plasma (FFP) or platelet transfusions as indicated.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing): Initiate high-dose intravenous proton pump inhibitor (PPI) therapy immediately for suspected non-variceal upper gastrointestinal bleeding (e.g., pantoprazole or esomeprazole administered as an 80 mg IV bolus, followed by a continuous infusion of 8 mg/h for 72 hours, or 40 mg IV every 12 hours). For patients with suspected or confirmed variceal hemorrhage due to cirrhosis, administer vasoactive splanchnic vasoconstrictors (e.g., octreotide 50 mcg IV bolus followed by a continuous infusion of 50 mcg/h for 2 to 5 days, or terlipressin 2 mg IV every 4 hours initially) alongside empirical antibiotic prophylaxis (e.g., ceftriaxone 1 g IV every 24 hours for 7 days) to prevent spontaneous bacterial peritonitis and sepsis.
  • Surgical / Interventional Indications: Urgent therapeutic endoscopy utilizing endoscopic clips, bipolar electrocoagulation, injection sclerotherapy, or band ligation for active bleeding. Endovascular transjugular intrahepatic portosystemic shunt (TIPS) placement or balloon tamponade (Sengstaken-Blakemore tube) for refractory variceal bleeding. Surgical intervention (such as oversewing of a bleeding ulcer or partial gastrectomy) is reserved for patients with persistent or recurrent hemorrhage refractory to endoscopic and endovascular therapy, or those with hollow viscus perforation.

8. Complications & Prognosis

  • Key acute complications include recurrent hemorrhage, aspiration pneumonia from hematemesis, hypovolemic shock, multiorgan dysfunction syndrome, and cardiac ischemia resulting from severe anemia. Overall mortality for acute upper gastrointestinal bleeding ranges from 2% to 10%, increasing significantly in elderly patients, those with underlying malignancy, cirrhosis, or multiorgan failure. The Glasgow-Blatchford score demonstrates superior predictive accuracy for identifying patients requiring clinical intervention compared to traditional post-endoscopy scoring systems, facilitating efficient resource allocation and safe early discharge for low-risk cohorts1,2.